Journal Logo

Articles by A. Gallamini

FRONTLINE BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY FOR STAGE 3/4 CLASSICAL HODGKIN LYMPHOMA: 3-YEAR UPDATE OF THE ECHELON-1 STUDY: S820

Gallamini, A.; Straus, D.; Dlugosz-Danecka, M.; More

HemaSphere. 3:362-363, June 2019.

DOSE DENSE ABVD (DD-ABVD) AS FIRST LINE THERAPY IN EARLY-STAGE UNFAVOURABLE HODGKIN LYMPHOMA (CHL): RESULTS OF A PHASE II, PROSPECTIVE, MULTI-CENTER STUDY BY FONDAZIONE ITALIANA LINFOMI: PS1237

Mazza, R.; Spina, M.; Califano, C.; More

HemaSphere. 3:563-564, June 2019.